Breaking News, Financial News

Financial Report: Biogen Idec 3Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec 3Q Revenues: $1.1 billion (+38%) 3Q Earnings: $207 million (+74%) YTD Revenues: $3.0 billion (+33%) YTD Earnings: $576.5 million (+32%) Comments: Tysabri sales recorded by Biogen, based on its collaboration with Elan, were $171 million (+172%) in the quarter. This consisted of $56 million related to product sold through Elan in the U.S. (based on $122 million of in-market sales); and $115 million related to product sold by Biogen internationally. Avonex sales were up 2...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters